- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00084422
N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study Of CEP-701 In Patients With Refractory Neuroblastoma (IND # 67,722)
RATIONALE: CEP-701 may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
PURPOSE: This phase I trial is studying the side effects and best dose of CEP-701 in treating young patients with recurrent or refractory high-risk neuroblastoma.
Study Overview
Detailed Description
OBJECTIVES:
Primary
- Determine the maximum tolerated dose of CEP-701 in pediatric patients with recurrent or refractory high-risk neuroblastoma.
- Determine the dose-limiting toxicity of this drug in these patients.
- Determine the pharmacokinetic behavior of this drug in these patients.
Secondary
- Determine the degree of TrkB tyrosine kinase inhibition activity present in the serum of patients treated with this drug.
- Correlate the degree of TrkB tyrosine kinase inhibition activity in these patients with dose level, pharmacokinetics, and antitumor activity data of this drug.
- Determine the antitumor activity of this drug in these patients.
OUTLINE: This is an open-label, dose-escalation, multicenter study.
Patients receive oral CEP-701 twice daily* on days 1-5, 8-12, 15-19, and 22-26. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
NOTE: *On day 1 of course 1 only, patients receive oral CEP-701 once instead of twice.
Cohorts of 3-6 patients receive escalating doses of CEP-701 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, the dose level is expanded up to 9 patients.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
-
-
-
California
-
Los Angeles, California, United States, 90027-0700
- Childrens Hospital Los Angeles
-
Palo Alto, California, United States, 94305
- Lucille Salter Packer Children's Hospital, Stanford University
-
San Francisco, California, United States, 94143
- UCSF Helen Diller Family Comprehensive Cancer Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago Comer Children's Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Children's Hospital Boston
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Comprehensive Cancer Center
-
-
New York
-
New York, New York, United States, 10032
- Morgan Stanley Children's Hospital of New York-Presbyterian
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229-3039
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-4318
- Children's Hospital of Philadelphia
-
-
Washington
-
Seattle, Washington, United States, 98105
- Children's Hospital and Regional Medical Center - Seattle
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
DISEASE CHARACTERISTICS:
Diagnosis of neuroblastoma confirmed by at least 1 of the following:
- Histology
- Demonstrates clumps of tumor cells in the bone marrow with elevated urinary catecholamine metabolites
- Recurrent or resistant/refractory disease
- Neuroblastoma metastatic to the bone marrow with granulocytopenia, anemia, and/or thrombocytopenia allowed
- High-risk disease
Patients in first response after completion of a prior front-line myeloablative regimen OR who were medically ineligible to receive a front-line myeloablative regimen must meet at least 1 of the following criteria:
Viable neuroblastoma determined by biopsy of a persistent lesion as seen on CT scan, MRI, or metaiodobenzylguanidine (MIBG) scan
- If lesion was irradiated, biopsy must be performed at least 4 weeks after completion of prior radiotherapy
- Morphologic evidence of tumor in bone marrow
- Second or greater response (without histologic confirmation) allowed
Meets at least 1 of the following criteria:
At least 1 unidimensionally measurable lesion on CT scan, MRI, or X-ray
- At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
- MIBG scan with positive uptake at a minimum of 1 site
- Bone marrow with tumor cells on routine morphology (not by NSE staining only) of bilateral aspirate and/or biopsy AND/OR at least 5 tumor cells/10^6 mononuclear cells in the bone marrow by immunocytologic analysis of 2 consecutive bone marrows performed at least 1 day but no more than 4 weeks apart
PATIENT CHARACTERISTICS:
Age
- 21 and under at diagnosis
Performance status
- Karnofsky 50-100% (for patients > 16 years of age)
- Lansky 50-100% (for patients ≤ 16 years of age)
Life expectancy
- More than 2 months
Hematopoietic
- See Disease Characteristics
- Absolute neutrophil count ≥ 1,000/mm^3
- Platelet count ≥ 50,000/mm^3 (transfusion independent)
- Hemoglobin ≥ 8.0 g/dL (red blood cell transfusions allowed)
Hepatic
- ALT and AST ≤ 3.0 times upper limit of normal (ULN)
- Total bilirubin ≤ 1.5 times ULN
Renal
- Creatinine ≤ 1.5 times normal OR
- Creatinine clearance or radioisotope glomerular filtration rate ≥ 60 mL/min
Cardiovascular
- Ejection fraction ≥ 50% by echocardiogram or MUGA OR
- Fractional shortening ≥ 28% or above lower limit of normal by echocardiogram
Pulmonary
- Lung function normal
- No dyspnea at rest
- No exercise intolerance
- No supplemental oxygen requirement
Other
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception
- No uncontrolled infection
- No other concurrent illness that would preclude study treatment
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Chemotherapy
- At least 2 weeks since prior biologic or non-myelosuppressive therapy and recovered
- More than 7 days since prior growth factors
- No prior allogeneic stem cell transplantation AND no extensive chronic graft-versus-host disease
- No concurrent growth factors except filgrastim (G-CSF) or sargramostim (GM-CSF) administered for neutropenia lasting for more than 7 days or for confirmed or clinical septicemia associated with neutropenia
Chemotherapy
- At least 3 months since prior myeloablative chemotherapy with stem cell transplantation
- At least 2 weeks since prior chemotherapy and recovered
Endocrine therapy
- No concurrent corticosteroid therapy except replacement therapy for adrenal insufficiency or treatment for increased intracranial pressure
Radiotherapy
- See Disease Characteristics
- Recovered from prior radiotherapy
- At least 6 weeks since prior therapeutic-dose MIBG
- At least 6 weeks since prior craniospinal or other radiotherapy involving significant bone marrow (i.e., total pelvis or total abdomen)
- At least 4 weeks since prior radiotherapy to any site biopsied
- At least 2 weeks since prior local palliative radiotherapy (small port)
Surgery
- Not specified
Other
- No prior CEP-701
No concurrent administration of any of the following CYP3A4 inhibitors:
- Cyclosporine
- Clotrimazole
- Ketoconazole
- Erythromycin
- Clarithromycin
- Troleandomycin
- HIV protease inhibitors
- Nefazodone
- Itraconazole
- Voriconazole
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Group
|
Given orally twice daily x 5 consecutive days followed by a two day rest.
28 days = 1 treatment course.
Courses repeated indefinitely without gap provided patient has recovered course from toxicities and no DLTs.
Dose level assigned according to the planned dose escalation schedule.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the maximum tolerated dose (MTD) of CEP-701 given on a twice daily chronic administration schedule (two days on , two days off) to children with high risk relapsed or residual neuroblastoma.
Time Frame: Within 28 days of treatment at each dose level.
|
Within 28 days of treatment at each dose level.
|
|
To determine dose limiting toxicities (DLTs) of CEP-701 given on this schedule
Time Frame: Within first 28 days of therapy.
|
Within first 28 days of therapy.
|
|
To characterize the pharmacokinetic (PK) behavior of CEP-701 in children with residual or refractory high-risk neuroblastoma.
Time Frame: Days 1,5 and 26 of first course only.
|
Participation in PK studies is voluntary and not a requirement for study entry.
|
Days 1,5 and 26 of first course only.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the degree of TrkB tyrosine kinase inhibition activity present in the serum of patients treated with CEP-701, and correlate these findings with dose level, pharmacokinetic and anti-tumor activity data.
Time Frame: Days 1,5 and 26 of first course only.
|
Days 1,5 and 26 of first course only.
|
To define the antitumor activity of CEP-701, within the confines of a Phase I study.
Time Frame: Evaluation at end of courses 1, 2, 4 and then every 4 courses until patient goes off therapy.
|
Evaluation at end of courses 1, 2, 4 and then every 4 courses until patient goes off therapy.
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Garrett M. Brodeur, MD, Children's Hospital of Philadelphia
Publications and helpful links
General Publications
- Maris J, Minturn J, Evans A, et al.: Phase I trial of the orally bioavailable TRK tyrosine kinase inhibitor CEP-701 in refractory neuroblastoma: a New Approaches to Neuroblastoma Therapy (NANT) study. [Abstract] Pediatr Blood Cancer 45 (4 Suppl 1): A-0.129, 416, 2005.
- Minturn JE, Villablanca J, Yanik GA, et al.: Phase I trial of lestaurtinib for children with refractory neuroblastoma (NB): A New Approach to Neuroblastoma Therapy (NANT) Consortium study. [Abstract] J Clin Oncol 28 (Suppl 15): A-9532, 2010.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000363630
- P01CA081403 (U.S. NIH Grant/Contract)
- NANT-2001-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroblastoma
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingStage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 2A Neuroblastoma | Stage 2B Neuroblastoma | Stage 3 Neuroblastoma | Stage 4 Neuroblastoma | Stage 1 Neuroblastoma | Stage 2 NeuroblastomaUnited States, Canada, Australia, New Zealand
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S NeuroblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingLocalized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 4 NeuroblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingRecurrent Neuroblastoma | Stage 4S Neuroblastoma | Stage 2A Neuroblastoma | Stage 2B Neuroblastoma | Stage 3 Neuroblastoma | Stage 4 NeuroblastomaUnited States, Canada, Australia, New Zealand
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 NeuroblastomaUnited States, Canada, Australia, New Zealand, Puerto Rico
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 NeuroblastomaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingLocalized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 4 NeuroblastomaUnited States, Puerto Rico, Canada, Australia, New Zealand, Netherlands, Saudi Arabia, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4 NeuroblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedLocalized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S NeuroblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Stage 4S NeuroblastomaUnited States
Clinical Trials on lestaurtinib
-
CephalonCompletedPolycythemia Vera | Essential ThrombocytosisUnited States
-
Ronald HoffmanNational Cancer Institute (NCI); Myeloproliferative Disorders-Research ConsortiumUnknownPolycythemia Vera | Essential Thrombocythemia | MyelofibrosisUnited States
-
M.D. Anderson Cancer CenterCephalonCompleted
-
CephalonCompletedAcute Myeloid LeukemiaUnited States, Canada, Australia, Germany, Israel, Italy, New Zealand, Poland, Romania, Russian Federation, Spain, Sweden, Ukraine
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingAcute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Childhood T Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand